Acadian Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Acadian Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-74,716	Closed	-$3M	–	1989
2026 Q1	$3M	Sell	74,716 -131,270	-64%	-$2.83M	﹤0.01%	837
2025 Q4	$5.17M	Buy	205,986 +193,533	+1,554%	+$4.54M	0.01%	646
2025 Q3	$280K	Buy	12,453 +2,371	+24%	+$55.3K	﹤0.01%	1338
2025 Q2	$174K	Sell	10,082 -13,894	-58%	-$257K	﹤0.01%	1321
2025 Q1	$522K	Buy	23,976 +22,052	+1,146%	+$609K	﹤0.01%	1073
2024 Q4	$61K	Hold	1,924	–	–	﹤0.01%	1431
2024 Q3	$55K	Buy	1,924 +1,666	+646%	+$61.7K	﹤0.01%	1766
2024 Q2	$9K	Hold	258	–	–	﹤0.01%	1704
2024 Q1	$15K	Sell	258 -6	-2%	-$382	﹤0.01%	1501
2023 Q4	$15K	Buy	+264	New	+$13.4K	﹤0.01%	1605
2021 Q3	–	Sell	-3,718	Closed	-$235K	–	1704
2021 Q2	$235K	Buy	+3,718	New	+$192K	﹤0.01%	1390

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acadian Asset Management's APLS Position: Q2 2026 in Review

Acadian Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 74,716 shares — an estimated $3M sold.

Acadian Asset Management first reported a position in APLS in Q2 2021 and held it in 11 quarters. The position peaked at $5.17M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Acadian Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Acadian Asset Management sold 74,716 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3M.
Acadian Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 11 quarters.
Acadian Asset Management's Apellis Pharmaceuticals position peaked at $5.17M in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.